University of North Dakota

UND Scholarly Commons
Theses and Dissertations

Theses, Dissertations, and Senior Projects

January 2013

Targeted Overexpression Of Metallothionein In
Endothelial Cells Mitigates Pulmonary Alveolar
Basement Membrane Thickening In Transgenic
Diabetic Ove Mice: An Unbiased Tem
Morphometric Analysis
Holly M. Hewitt

Follow this and additional works at: https://commons.und.edu/theses
Recommended Citation
Hewitt, Holly M., "Targeted Overexpression Of Metallothionein In Endothelial Cells Mitigates Pulmonary Alveolar Basement
Membrane Thickening In Transgenic Diabetic Ove Mice: An Unbiased Tem Morphometric Analysis" (2013). Theses and Dissertations.
1542.
https://commons.und.edu/theses/1542

This Thesis is brought to you for free and open access by the Theses, Dissertations, and Senior Projects at UND Scholarly Commons. It has been
accepted for inclusion in Theses and Dissertations by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.

TARGETED OVEREXPRESSION OF METALLOTHIONEIN IN ENDOTHELIAL
CELLS MITIGATES PULMONARY ALVEOLAR BASEMENT MEMBRANE
THICKENING IN TRANSGENIC DIABETIC OVE MICE: AN UNBIASED TEM
MORPHOMETRIC ANALYSIS

by

Holly M. Hewitt
Bachelor of Arts, Concordia College, 2010

A Thesis
Submitted to the Graduate Faculty
of the
University of North Dakota
in partial fulfillment of the requirements

for the degree of
Master of Science

Grand Forks, North Dakota
December
2013

Copyright 2013 Holly M. Hewitt
ii

PERMISSION

Title:

Targeted Overexpression of Metallothionein in Endothelial Cells
Mitigates Pulmonary Alveolar Basement Membrane Thickening in
Transgenic Diabetic OVE Mice: An Unbiased TEM Morphometric
Analysis

Department:

Anatomy and Cell Biology

Degree:

Master of Science

In presenting this thesis in partial fulfillment of the requirements for a graduate
degree from the University of North Dakota, I agree that the library of this University
shall make it freely available for inspection. I further agree that permission for extensive
copying for scholarly purposes may be granted by the professor who supervised my
thesis work, or in their absence, by the chairperson of the department or the dean of the
School of Graduate Studies. It is understood that any copying or publication or other use
of this thesis or part thereof for financial gain shall not be allowed without my written
permission. It is also understood that due recognition shall be given to me and to the
University of North Dakota in any scholarly use which may be made of any material in
my thesis.

Holly M. Hewitt
November 21, 2013

iv

TABLE OF CONTENTS
LIST OF FIGURES .......................................................................................................... vii
LIST OF TABLES ........................................................................................................... viii
ACKNOWLEDGMENTS ................................................................................................. ix
ABSTRACT...................................................................................................................... xii
CHAPTER
I.

INTRODUCTION .......................................................................................1
Chronic Complications of Diabetes Mellitus ...................................3
The Extracellular Matrix and Diabetic Induced Alterations ............4
Hyperglycemia and Reactive Oxygen Species ................................6
Antioxidant Therapy and Protection against
Basement Membrane Thickening ....................................................9
Histology of Pulmonary Tissue .....................................................13
Objectives of Current Study...........................................................16

II.

MATERIALS AND METHODS ...............................................................18
Research Animals ..........................................................................18
Genotyping.....................................................................................19
Quantification of MT in Pulmonary Tissues .................................21
Vascular Perfusion and Tissue Preparation of Microtomy ............23
Statistics .........................................................................................31

v

III.

RESULTS ..................................................................................................32
General Condition of Animals .......................................................32
Pulmonary Morphology .................................................................33
Pulmonary Alveolar Basement Membrane
(PABM) Morphometry ..................................................................36
Analysis of MTI/II Expression ......................................................37

IV.

DISCUSSION ............................................................................................39

APPENDIX ........................................................................................................................47
REFERENCES ..................................................................................................................64

vi

LIST OF FIGURES
Figure

Page

1.

General appearance of 150 day-old mice...............................................................49

2.

Toluidine blue stained light micrograph with higher magnification transmission
electron micrograph inset of terminal respiratory region of 150 day-old FVB
control mouse lung.................................................................................................50

3.

Transmission electron micrograph of 150 day-old FVB control mouse lung .......52

4.

Transmission electron micrograph of two adjacent respiratory filtration
barriers in lung of 150 day-old FVB control mouse ..............................................53

5.

Representative transmission electron micrographs of respiratory filtration
barriers in 60 day-old FVB, Jtmt, OVE, and OVEJtmt mice ................................54

6.

Representative transmission electron micrographs of respiratory filtration
barriers in 150 day-old FVB, Jtmt, OVE, and OVEJtmt mice ..............................56

7.

Mean pulmonary alveolar basement membrane thickness in 60 day-old
mice ........................................................................................................................58

8.

Mean pulmonary alveolar basement membrane thickness in 150 day-old
mice ........................................................................................................................59

9.

Age-related mean pulmonary alveolar basement membrane thickness in
60 day-old and 150 day-old mice...........................................................................60

10.

Representative light micrographs of paraffin embedded kidney cortex and
lung immunohistochemically stained for MTII .....................................................61

11.

Average pulmonary MTII µg/mg total tissue protein) in FVB control (n=2),
Jtmt transgenic (n=2), OVE (n=2) and OVEJtmt (n=2) transgenic and
bi-transgenic animals ±S.D. ...................................................................................63

vii

LIST OF TABLES
Table

Page

1.

Animal genotype, number of animals, number of epoxy blocks sectioned,
number of micrographs taken, and number of measurements made per
micrograph for orthogonal intercept calculation of true PABM thickness ............48

2.

Mean body weight, blood glucose, and HbA1c values from 60 and 150 day-old
FVB, Jtmt, OVE and OVEJtmt mice ± S.D.. .........................................................49

3.

Age-related mean pulmonary alveolar basement membrane thickness in 60 and
150 day-old mice....................................................................................................60

viii

ACKNOWLEDGMENTS
I have many people to thank for helping me throughout my years as a graduate
student. For the continuous support and encouragement from family, friends, faculty, and
colleagues, I thank you from the bottom of my heart. You have helped me endure the
rough patches, but more importantly, celebrate my achievements in graduate school.
I would like to express my sincere gratitude to my advisor, Dr. Edward Carlson.
You have been the kindest and most genuine role model I could have ever asked for.
Without you, I would not have been able to complete my degree and I sincerely
appreciate your taking a chance on me. You have provided me with guidance every step
of the way while also allowing me freedom to grow on my own. Your confidence in me
has provided me the foundation I needed to have confidence in myself. I will never forget
your tenacity and excitement for science, fortitude in mentoring students, and optimistic
approach in everything you encounter, all of which I will bring with me on my future
endeavors. Thank you.
Thank you, Drs. Pat Carr and Mandy Meyer. You have been wonderful
committee members and I appreciate you taking the time out of your busy lives to
provide me with advice, guidance, and support. You are both fantastic educators that I
look up to and I hope someday to be even half the instructors that you are. Thank you for
your time, patience, and leadership.
Were it not for my parent’s encouragement to be curious and investigate from a
young age, I would not have developed the scientific inquiry that I possess today. Their
ix

continual support throughout my years of schooling has gotten me here today, and to
them, I owe everything.
To my husband, Tony Hewitt, thank you for studying chemistry with me in our
undergraduate education and deciding that we were such good study partners, we should
get married. I would not have been able to succeed and complete as many goals as I have
without your encouragement and faith in me. Words will never be able to express how
much your love and support have meant to me.
To Donna Laturnus, thank you for having such a kind heart and sharing it with
everyone you meet. Because of you, from my very first day in lab, I have always felt at
home. You have provided me with a genuine friendship that I will always cherish.
Additionally, I have you to thank for teaching me so many techniques in the lab that were
not only essential for my project, but for future experiences as well.
To Dr. John Swinscoe, thank you for help with the ELISA protocol and having
patience with me when showing me laboratory techniques. I also appreciate your
feedback and advice throughout the past year, I’ve learned so much.
I would also like to express my gratefulness to Kim Young and Bonnie Kee. You
have both been so helpful in anything and everything that I have needed. Kim, your
eagerness to assist me with integral parts of many experiments has helped me accomplish
many goals and meet numerous deadlines. I am thankful of your kind heart and greatly
appreciate your help. Bonnie, you have assisted me, even with only a moment’s notice,
with critical aspects of my graduate education, including formatting this thesis. I
appreciate everything you have done and the patience you have shown me. Without you,
I would not have been able to graduate. You deserve so much recognition for your hard

x

work and dedication not only to the University, but also to the students, faculty, and staff.
Thank you for all that you do.

xi

ABSTRACT
Damage to small blood vessels in diabetes mellitus (DM) is largely the result of
hyperglycemia-driven oxidative stress. This is manifested morphologically by capillary
basement membrane (BM) thickening, the hallmark feature of chronic complications of
DM. In an effort to demonstrate pulmonary alveolar BM (PABM) thickness increase in
DM and to demonstrate for the first time, mitigation of the increase utilizing antioxidant
therapy, we crossed the severely diabetic transgenic mouse (OVE) with Jtmt, our recently
developed transgenic animal model that overexpresses the antioxidant metallothionein
(MT) in endothelial cells. Unbiased TEM morphometry demonstrated that PABM widths
in diabetic (OVE) mice were significantly (+20%) thickened. Remarkably, however, the
bi-transgenic OVEJtmt progney exhibited statistically significant protection against DMderived BM thickening. These results provide evidence for a direct role of oxidative
damage to endothelial cells in diabetic mice and show that protection of these cells can
reduce one of the primary features of diabetic microangiopathy.

xii

CHAPTER I
INTRODUCTION
Diabetes mellitus (DM) is a serious and potentially debilitating disease that is
considered an epidemic in the Western hemisphere including the United States where
approximately 8.3% of the population is diabetic (Center for Disease Control, 2011). In
2000, more than 171 million people were afflicted with the disease worldwide and it is
anticipated that by the year 2030, more than 366 million people will be diagnosed (Wild
et al., 2004; WHO, 2006). Importantly, by 2030, DM is predicted to be the seventh
leading cause of death in the U.S. due to the serious vascular complications that
accompany it (WHO, 2006). Extensive research has been carried out in an effort to
eliminate DM and to mitigate its chronic complications. Nevertheless, additional studies
will be required to understand the causes of DM and reduce the escalating number of
diagnoses and increased health care costs each year.
Diabetes is characterized as a group of metabolic diseases, in which
hyperglycemia and glucose intolerance transpire, which results in diseased
microvasculature. The two main types of DM are Type I (T1D) and Type II (T2D). Each
is characterized by chronic hyperglycemia as well as deregulated metabolism of fats,
proteins, and carbohydrates (McCance and Heuther, 2010).
Type I DM is an autoimmune condition caused by malfunctioning primary
pancreatic beta cells. This condition is also known as Insulin-Dependent Diabetes (IDD)
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because the pancreas produces and secretes insufficient amounts of insulin (Jahromi and
Eisenbarth, 2007). Accordingly, diabetic patients depend on synthetic insulin for
maintenance of appropriate serum blood sugar and survival (Jahromi and Eisenbarth,
2007). Type I diabetes accounts for approximately 10% of all diagnosed cases, and its
incidence has nearly doubled over the past twenty years (Nokoff and Rewers, 2013). In
the United States, individuals under the age of 20 are especially at risk of developing
T1D, as shown by an increase in diagnoses in this age group by 23% between 2001 and
2009 (Nokoff and Rewers, 2013). It is hypothesized that this increase is correlated to the
epidemic of childhood obesity.
Within the Type I class, there are two subcategories: autoimmune diabetes
[type 1A (T1A)] and nonimmune diabetes [type 1B (T1B)] (Jahromi and Eisenbarth,
2007). Type 1B diabetes, also known as idiopathic diabetes, often occurs as a secondary
condition initiated by other ailments affecting the pancreas, such as pancreatitis,
neoplasia, and cystic fibrosis (McCance and Heuther, 2010). Type 1A diabetes is more
common than T1B and is triggered by a combination of genetic and environmental
factors resulting in the overproduction of autoantibodies that destroy pancreatic beta cells
(Jahromi and Eisenbarth, 2007).
Environmental factors that have been strongly correlated with the cause of T1D
include viral infections such as: mumps, enteroviruses, endogenous retroviruses,
parvovirus, rotovirus, cytomegalovirus, and congenital rubella (Richer and Horwitz,
2008), drugs and chemicals such as: streptozotocin, alloxan, pentamidine, and vacor,
(McCance and Heuther, 2010) and dietary factors such as, bovine milk and cereal
(Jahromi and Eisenbarth, 2007).
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In addition to environmental contributors, a strong link between specific genetic
backgrounds and the development of autoimmune diseases, including T1D, have been
made. The histocompatibility leukocyte antigen (HLA) and its associated genetic variants
have been the most compelling risk factor in familial diabetic cases (Nokoff and Rewers,
2013).
Type II diabetes is by far the most common type of diabetes, and accounts for
90-95% of diagnosed cases (Nokoff and Rewers, 2013). Onset of T2D often occurs later
in life, with an average age between 45-64 years. Incidence rates are increasing in all age
groups in the United States, and the risk of developing the disease increases after the age
of 40 (McCance and Heuther, 2010). Obesity significantly increases the risk for
developing the disease and the risk is related to the duration, degree, and distribution of
obesity (McCance and Heuther, 2010). The major distinction between T2D and T1D is
the development of insulin resistance in T2D, as well as decreased insulin secretion over
the duration of the illness (Wright et al., 2006).
Genetic predisposition, age, and other environmental factors contribute to the risk
of developing DM and treating its inevitable complications is essential. The
pathophysiology of these complications must be understood because the increasing
morbidity and mortality of DM is caused by the associated chronic complications in the
macro- and microvasculature (Sheetz, 2002).
Chronic Complications of Diabetes Mellitus
Insulin resistance and chronic hyperglycemia have been implicated in the
pathogenesis of chronic complications associated with DM (Brownlee, 2001). Chronic
complications of DM are serious pathological states associated with the condition that
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contribute to significantly increased health care costs and major obstacles in diabetes
therapy. The most common chronic complications include; diabetic nephropathy, diabetic
cardiomyopathy, diabetic neuropathy, and diabetic retinopathy.
Macrovascular complications occur when arteries supplying the brain, heart, and
lower extremities become atherosclerotic (Brownlee, 2001). Diseased large vessels
contribute to the fact that diabetic patients have an increased incidence of myocardial
infarction, stroke, and lower limb amputation (Brownlee, 2001). Microvascular
complications are pathological states of smaller blood vessels supplying the retina,
kidneys, and peripheral nerves. Atherosclerotic microvasculature is a major cause of
blindness, end stage renal disease, and peripheral nerve damage in many diabetic patients
(Brownlee, 2001).
Interestingly, a unifying pathophysiological change in these chronic
complications is the thickening of basement membranes (BM) - a specialized component
of the extracellular matrix (ECM) associated with all non-connective tissues including the
endothelium of the macro- and microvasculature (Ozsahin et al., 2006).
The Extracellular Matrix and Diabetic Induced Alterations
The ECM is a biophysical component of cellular networks that maintains
structural and mechanical properties of the cells (Smits et al., 2010). It not only has roles
in maintaining the structure of the cellular network, but also in signaling cascades for the
proper functioning of cells. Fibrous proteins that comprise the ECM are located between
clusters of cells within all tissue and provide tensile strength, routes for communication,
and movement of cells within tissues (Kalluri, 2003).
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Basement Membranes
Basement membranes are specialized ECM ranging between 50-350 nm in
thickness and are synthesized by epithelial cells (Kalluri, 2003). They are arranged as a
sheet-like structure located between cells, cell surfaces, and the interstitium, serving as a
partition between cell monolayers and the connective tissue space (Yurchenco, 2009).
Cell monolayers produce and secrete specialized glycoproteins that form the BM on their
basolateral surfaces (Yurchenco, 2009). Epithelia (including the endothelium) throughout
the entire body are in direct association with BMs for tissue organization, structural
support, and regulation in cellular signaling (Kalluri, 2003).
The biochemical composition of BMs varies from tissue to tissue and these
differences are due to tissue-specific expression of protein isoforms, alternative splicing,
and posttranslational modifications (LeBleu, 2007). Composition of BMs can also be
relatively dynamic based on the physiologic or pathophysiologic state of tissues (LeBleu
et al., 2007). Despite the heterogeneous expression of these molecules in tissues, there are
several proteinaceous components found universally in BMs.
Collagen (type IV), laminin, nidogen/entactin, and heparan sulfate proteoglycans
(perlecan and agrin) comprise the majority of BM molecules and are intricately involved
in its functions (Yurchenco, 2009). These proteins are extensively coupled to other
molecules involved in signaling cascades that control cell motility, differentiation, the
cell cycle, and the expression of other genes and proteins (Yurchenco, 2009).
Alterations in BM
Thickening of the BM, especially in the kidney, is a primary pathophysiological
feature found in DM patients and is a hallmark of the disease (Bergstrand and Bucht,
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1959). The hyperglycemic environment present in DM antagonizes the homeostatic
nature of cells, which activates a biological stress response. One consequence of a
cellular stress response is the potential alteration of BM composition (Rohrbach and
Martin, 1982).
One of the first diabetic induced alterations of BMs reported was in the kidney
(Kimmelstiel and Wilson, 1936). Within the renal glomerular mesangium, a network of
mesangial cells (intercapillary cells) and mesangial matrix provide mechanical support
for glomerular capillaries (Suzuki et al., 1963). The renal mesangial cells respond to
injury, by cellular proliferation and increased deposition of matrix molecules, known
pathologically as Kimmelstiel-Wilson nodules. These are observed in patients with
diabetic nephropathy (Suzuki et al., 1963). Diabetic nephropathy is characterized by
increased deposition of ECM proteins in the mesangium as well as BM thickening in the
glomerulus (Mason and Wahab, 2003).
It is widely accepted that increased synthesis of ECM molecules in DM is a result
of the activation of several pathways, leading to either the increased synthesis of ECM
proteins and/or the decreased degradation of aged ECM proteins (i.e. decreased ECM
turnover).
Hyperglycemia and Reactive Oxygen Species
Hyperglycemia has been shown to cause adverse effects on many biochemical
pathways in vascular tissues and one of these consequences is the excess production of
reactive oxygen species (ROS) which contributes to increased cellular and extracellular
oxidative stress (Son, 2007). In general, cells respond to this stress by activating various
intracellular signaling pathways, and consequently, gene activation (Son, 2007).
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Hyperglycemia-induced intracellular signaling has been shown to contribute to
BM thickening in most tissues through pathways activated by the presence of ROS
(Sheetz, 2002). Increased levels of ROS in T1D and T2D transpire through a series of
complex and intertwined molecular pathways.
Reactive oxygen species, at moderate levels, are involved in various molecular
mechanisms and signaling pathways to produce normal cellular responses. The oxidation
of water, or reduction of molecular oxygen, to give products such as superoxide anion
(O2-), hydrogen peroxide (H2O2) and hydroxyl radical (+OH) in the mitochondria provide
biological systems with the majority of ROS (Rains et al., 2011). When ROS are present
in higher than normal amounts, detrimental consequences to cells, including lipid
membrane destruction, oxidative damage to DNA, excess cross-linking of proteins, and
inappropriate activation of stress related signaling pathways could disrupt cell behavior
(Son, 2007).
The mechanisms behind hyperglycemia-induced vascular damage are largely
driven by the action of ROS. Theories involving four molecular pathways are recognized
in causing glucose-mediated vascular damage, including, the aldose reductase (polyol
pathway) theory, activation of protein kinase C (PKC) isoforms, the reactive oxygen
intermediate theory, and increased intracellular formation of advanced glycation endproducts (AGEs) (Sheetz, 2002).
The aldose reductase (polyol pathway) mechanism is activated when intracellular
glucose concentrations are elevated (Sheetz, 2002). Aldose reductase is an enzyme that
utilizes nicotinamide adenine dinucleotide phosphate (NADPH) as a reducing agent in
the conversion of glucose to sorbitol (Madonna, 2011). As a result of the increase of
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aldose reductase in endothelial cells, sorbitol is oxidized by sorbitol dehydrogenase,
leading to the production of fructose (Sheetz, 2002). This process occurs with the coupled
reduction of NAD+ to NADH (Sheetz, 2002). Overall, the increased activity of aldose
reductase and reduced levels of NADPH causes downstream disturbance of the redox
balance within the vascular tissues (Sheetz, 2002).
Activation of PKC isoforms is also intricately involved in the development of
diabetic vascular complications. In hyperglycemic environments, PKC is activated and is
able to alter cellular behavior in various ways. Intracellular hyperglycemic environments
trigger the activation of a second messenger, diacylglycerol (DAG) (Madonna, 2011). In
endothelial cells, DAG activates PKC, which triggers intracellular events to alter gene
expression. Specifically, PKC activation leads to BM thickening by the activation of
transforming growth factor (TGF) β, collagen, and fibronectin (Madonna, 2011). In
addition to the activation of DAG, elevated glucose concentrations increase overall
glycolytic pathway activity and the levels of glyceraldehyde-3-phosphate (GAP) inside
endothelial cells (Sheetz, 2002). Oxidative phosphorylation of GAP contributes to the
activation of reactive oxygen intermediates (ROI), initiating an oxidative stress response
of vascular endothelial cells (Sheetz, 2002).
The ROI pathway directly contributes to the oxidative environment of endothelial
cells and vascular damage through several mechanisms, including oxidative
phosphorylation of GAP in the previously described PKC signaling pathway. An increase
in glucose metabolism through the glycolytic pathway and the tricarboxylic acid cycle
(TCA) increases mitochondrial adenosine triphosphate (ATP) synthesis by oxidative
phosphorylation (Nishikawa, 2000). Several byproducts of this biochemical process
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include free radicals, such as the superoxide anion. Increased levels of superoxide anion,
as previously discussed, generates an oxidative environment and stress on vascular tissue,
ultimately leading to cellular damage and altered cellular behavior.
A fourth mechanism involved in the development of diabetic chronic
complications is the AGE pathway. Advanced glycation end products are proteins that
become altered, and irreversibly modified, in the normal course of aging (Sheetz, 2002).
Increased levels of glucose cause additional covalent modifications and crosslinking of
proteins and in diabetics this process has been described as a process of accelerated aging
(Monnier, 1984). Further cellular dysfunction and vascular damage occur by AGEs
binding receptors to advanced glycation end products (RAGE) (Goh and Cooper, 2008).
When these transmembrane receptors are activated, additional signaling events are also
initiated, such as the activation of mitogen-activated protein kinase (MAP) pathway,
which leads to endothelial cell dysfunction (Schmidt, 2000).
A common relationship exists between these four pathways; they are all initiated
by hyperglycemia and their activation results in an overproduction of superoxide, which
has been strongly associated with hyperglycemia-induced oxidative stress responses in
diabetics (Madonna, 2011). Although it remains unclear as to which mechanism is the
primary source of hyperglycemia-induced production of ROS, it could be the
combination of these pathways that contribute to vascular complications (Velic et al,
2013).
Antioxidant Therapy and Protection against Basement Membrane Thickening
The overproduction of free radicals in diabetics is initiated through glucose
oxidation, nonenzymatic glycation of proteins, and oxidative degradation of glycated
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proteins (Cai, 2004). One way of neutralizing diabetic oxidative damage, and the
consequences of oxidative stress (BM thickening), is through the protective properties of
antioxidants.
In this regard, one of the most potent antioxidants referenced in the literature is
metallothionein (MT). Metallothioneins are a family of proteins known to bind to metals,
such as zinc (Zn), cadmium (Cd), copper (Cu), and iron (Fe) and cysteine-rich residues in
cells (Cai, 2004). There are at least ten known isoforms of MT in humans and they are
further classified into major and minor groups (Thirumoorthy et al., 2011).
Metallothionein isoforms have a wide range of protective characteristics, offering
scavenging against free radicals such as the hydroxyl radical and peroxynitrite, which are
considered the most active radicals (Cai, 2004). Due to its various protective properties
and global expression throughout the body, MT isoforms I and II (MTI/II) comprise the
major group of MTs (Thirumoorthy et al., 2011). As a scavenger of various radicals, MT
has been shown to be >50 times more powerful than other antioxidants, and thus, MT
offers promising protective properties against oxidative stress-related damage in cells and
tissues of diabetic patients (Kumari et al., 1998).
Antioxidant Therapy
Antioxidant therapy has been studied in various animal models to counterbalance
the overproduction of ROS in diabetic and insulin-resistant mice (Son, 2007). One such
mouse, the OVE26 (herein referred to as OVE), is a transgenic diabetic mouse that has
been shown to be a valuable model of human type I DM (Zheng et al., 2008). The OVE
mouse was developed by introducing a minigene to overexpress calmodulin in the
pancreatic beta cell (Epstein et al., 1989). Overexpression of calmodulin in the beta cell
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interrupts the physiological response of these cells to produce and secrete insulin. This
interruption of insulin production makes the OVE mouse an excellent model to study the
genetic background of insulin secretion (Epstein et al., 1992). These transgenic mice can
easily be identified by the phenotypic marker, small eyes. The presence of small eyes is
caused by the intentional cointegration of the GR19 gene (Liang et al., 2002). The OVE
mouse is maintained on the Friend virus B-type susceptibility (FVB) background. The
FVB mice are an inbred mouse strain maintained by the National Institutes of Health
(NIH) for studying transgenic mice (Taketo et al., 1991).
With the establishment of a reliable mouse model that demonstrates common
characteristics of human DM, it is possible to study the effects of antioxidant therapy.
Recent studies utilizing these diabetic and transgenic mouse models provide evidence
that oxidative stress in diabetics can be mitigated. In 2003, Carlson and co-workers
carried out morphometric analyses of capillary BM thickness in various tissues in 350
day-old OVE diabetic and normal FVB mice. Interestingly, in addition to the renal
glomerulus, several other tissues were susceptible to hyperglycemia-induced capillary
BM thickening. These included skeletal and cardiac muscle, retina and choroid,
peripheral nerve, lung, and pancreas (Carlson et al., 2003). Not surprisingly, the renal
glomerulus and ocular retina exhibited the highest susceptibility to BM thickening in
diabetic mice. However, the lung and respiratory diaphragm also demonstrated
significant capillary BM thickening in OVE transgenic diabetic mice.
Early work with the OVE mouse and potential antioxidant protection against BM
thickening was conducted with the development of a transgenic mouse that
overexpressed MT in myocardial cells (Mt) (Liang et al., 2002). Progeny of the OVE and
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Mt mice showed significant reduction in myocardial oxidative damage and decreased
myocardial capillary BM thickening in transgenic diabetic mice. Furthermore, targeted
overexpression of MT provided antioxidant protection against oxidative stress in cardiac
myocytes and also protected against diabetic cardiomyopathy (Velic et al., 2013).
Metallothionein also has been targeted to other cells in efforts to study its
protective properties against diabetic nephropathy (DN). The Nmt transgenic mouse
overexpresses MT in the podocytes of the kidney (Zheng et al., 2008). Moreover,
progeny of OVE and Nmt mice show significant protection against DN and associated
glomerular injury (Carlson et al., 2013). Severe albuminuria, glomerular filtration barrier
damage, and changes in glomerular endothelial and mesangial cell numbers are all
consequences of DN, and all are reduced by the presence of targeted MT in podocytes
(Carlson et al., 2013).
Overexpression of MT in cardiac myocytes and renal podocytes strongly
supported the theory of antioxidant therapy in treating oxidative stress related damage to
these specific tissues. This stimulated a number of investigators to begin efforts toward
building a transgenic mouse that overexpressed MT in endothelial cells, a cell type
ubiquitously distributed with the macro- and microvasculature. Accordingly, the
endothelial cell, appropriately armed with overexpressed MT could show the potential to
reduce vascular BM thickening globally.
Jtmt Mice
To test the hypothesis of antioxidant protection against diabetes-induced oxidative
damage in other tissues, the human MTII gene needed to be introduced, universally, into
endothelial cells. In response to this requisite, a Jtmt transgene was designed and purified
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by Teiken (2011) to overexpress the human MTII gene, and the purified Jtmt transgene
was inserted into the developing zygote (into the pronucleus) of FVB mouse embryos
(Transgenic Mouse Laboratory, Children’s Hospital Research Foundation of Cincinnati).
The Jtmt transgene was inserted into the pHHNS plasmid, which contains the
Tie2 promoter and enhancer for murine endothelial cells. The Tie2 promoter and
enhancer ensured that the Jtmt gene would be expressed specifically in the endothelium,
thus creating the Jtmt mouse line (Teiken, 2011).
The establishment of a transgenic mouse that overexpresses MT universally in its
endothelial cells provides a unique vehicle to study antioxidant protection in a wide
variety of tissues in control and transgenic mouse models. One such tissue, the lung, is a
particularly appropriate candidate for experimentation. As mentioned earlier, the lung is
susceptible to hyperglycemia-induced significant BM thickening (Carlson et al., 2003).
Its similar structural arrangement to the glomerular filtration barrier in the kidney could
offer insight into the specific cellular mechanisms in BM thickening of each tissue.
Additionally, as the largest microvascular structure in the body (Shafiee et al., 2013), the
lung warrants further exploration into potential chronic diabetic pulmonary
complications, specifically any morphological alterations in the pulmonary alveolar
basement membrane (PABM).
Histology of Pulmonary Tissue
The respiratory system is divided into two functional parts; the conducting portion
and the respiratory portion. The conducting portion includes the air passageways from the
nasal cavity through the level of the terminal bronchioles (nose, pharynx, larynx, trachea,
bronchi) (Sorokin, 1988). The respiratory portion of the lungs includes the small air
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spaces from the respiratory bronchioles to the level of the alveoli (respiratory
bronchioles, alveolar ducts, and alveoli) (Sorokin, 1988). The conducting portion
functions to bring air in and out of the lungs, whereas the respiratory portion provides an
outlet for gas exchange.
Gas exchange occurs through the thin walled structures, termed pulmonary
alveoli. More than 300 million alveoli in the human lung provide at least 143 square
meters of surface area for gas exchange between the inspired air and circulating blood
(Sorokin, 1988).
The alveolar epithelium consists of two cell types, including the Type I and Type
II alveolar cell. Type I alveolar cells cover a large surface area and are a specialized
squamous epithelium that on average are less than 0.2 µm thick (Sorokin, 1988). Type I
alveolar cells are the primary alveolar cells involved in gas exchange in conjunction with
the endothelium of the alveolar capillaries (Apparao et al., 2010). Type I alveolar cells
are connected to one another and to Type II alveolar cells by occluding junctions (Bloom
and Fawcett, 1986).
Type II alveolar cells are located in the margins of alveoli and are classified as a
cuboidal epithelium (Apparao et al., 2010). These secretory cells synthesize and secrete
pulmonary surfactant, which is a phospholipid that coats the epithelial lining of the
alveoli (Bloom and Fawcett, 1986). Type II cells are not primarily involved in gas
exchange, but are structurally related to the organization of the blood-air barrier. Type II
cells also support host defense in immune responses and act as epithelial progenitors
(Apparao et al., 2010).
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Together Type I and Type II alveolar cells comprise one side of the blood-air
barrier; the opposite surface is made up of capillary endothelial cells. These capillaries,
which bring blood to the blood-air barrier of the lung, are surrounded by the interstitium
of the alveolar septa. Pulmonary epithelium overlie the capillaries at the points where gas
exchange occurs - and in these areas, the interstitum of the lung is reduced to a thin layer
of BM (Sorokin, 1988). Thus, oxygen exchange occurs through the blood-air barrier,
beginning with the endothelium of the capillaries, followed by the BM of alveolar
capillaries, the thin and sometimes indistinguishable interstitial space, the BM of the
alveolar epithelium (type I cells), and finally the alveolar epithelium itself (Sorokin,
1988). The alveolar epithelial BM and endothelial BM of the capillary frequently are
fused to form the PABM.
Pulmonary Alveolar Basement Membranes
The PABM in the lung is also referred to as the basement membrane zone (BMZ)
(Evans et al., 2010). The terms basal lamina (BL), basement membrane zone (BMZ), and
PABM are used interchangeably in the literature. Typically, BM is utilized more often in
reference to the structure as it appears in light microscopy whereas BMZ and BL refer to
the same structure at the electron microscopic level or when describing its molecular
components. The BMZ (herein referred to as the PABM) is comprised of following three
layers; the lamina lucidia, lamina densa, and lamina reticularis (Evans et al., 2010).
On the basolateral surface of the alveolar cell, the lamina lucidia (LL) forms the
first layer of the PABM. This layer is comprised of collagen (XVII), laminin (5, 6, and
10), integrins (α6ß4), laminin (1), and collagen (IV) (Evans et al., 2010). The latter two
proteins are found at the cellular-matrix interface of the LL (Evans et al., 2010). The
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lamina densa is formed primarily by proteins such as entactin/nidogen, proteoglycans
(perlecans, bamacan, agrin, collagen XVIII), and stored growth factors (FGF-2) (Evans et
al, 2010). At the matrix interface, the lamina reticularis (LR) is comprised of the
following molecular components: collagen (I, III, V, VI, and VII), proteoglycans
(perlecan, bamacan, and collagen XVIII), as well as stored growth factors (FGF-2)
(Evans et al., 2010).
In the lung, the lamina reticularis (LR) is the basal portion of the BM and has also
been referred to as the reticular BM in the literature (Evans et al, 2010). The LR is
variable in its distribution throughout the body and is not found in all tissues. However, it
is present in a number of tissues with multilayered epithelium, including the lung (Evans
et al., 2010). In pathological states, the LR is often affected, as it serves as a regulator of
cytokine movement between the alveolar epithelium and the ECM (Evans et al., 2010).
Interactions involving ECM macromolecules and the LR have the potential to alter
cellular behavior. Diseased states can interrupt normal signaling cascades by altering
cellular environments – such as the hyperglycemic environment generated by chronic
DM.
Objectives of Current Study
Elucidating the molecular and cellular biological pathways contributing to the
diseased microvasculature in DM is an important area of investigation. As previously
stated, BM thickening is one of the hallmarks of microvascular complications in DM
(Carlson et al., 2003). It is the first pathophysiological change in several tissues,
including the glomerulus of the kidney, myocardial capillaries in the heart, as well as the
capillaries of the retina (Liang, 2002, Carlson et al., 2003, 2012).
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In this regard, the lung is the most highly vascularized organ in the body (Sorokin,
1988), and since DM is principally a disease of small blood vessels, it seems reasonable
that the blood-air barrier is highly vulnerable to diabetic microangiopathy, (Shafiee et al.,
2013) including PABM thickening.
Accordingly, my working hypothesis is that PABMs exhibit DM-related
thickening in severely diabetic transgenic mice. Moreover, this structural alteration is
mitigated by specific endothelial targeted overexpression of MT.
If my hypothesis is correct, the results will show that PABM are thicker in
severely diabetic (OVE) mice than in the healthy control (FVB) and (Jtmt) groups.
Furthermore, the bi-transgenic (OVEJtmt) group will show a reduced or even eliminated
PABM thickness increase, strongly suggesting possible antioxidant protection against
hyperglycemia-driven pulmonary oxidative stress.
Results of this study will contribute significant and fundamental data to the
literature on diabetic BM disease. Furthermore and importantly, baseline ultrastructural
data on the respiratory filtration barrier and a possible first definition of “diabetic
pulmonopathy” and potential pulmonoprotection against vascular injury, will offer an
avenue of new and compelling diabetes research.
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CHAPTER II
MATERIALS AND METHODS
Research Animals
Four groups of mice were utilized in this study. Each group was further divided
into two age cohorts including 60 and 150 day old mice. All groups consisted of at least
12 (six, 60 day-old and six, 150 day-old) animals. Group I was comprised of healthy
control Friend virus B-type (FVB) mice (Taketo, 1991). Group II was age-matched,
transgenic and severely diabetic mice (OVE) (Epstein et al., 1989, 1992). Group III
consisted of at least 12 age-matched, transgenic (Jtmt) mice that overexpress
metallothionein (MT) in endothelial cells (Teiken, 2011). Group IV consisted of at least
12 age-matched, bi-transgenic and severely diabetic (OVEJtmt) mice. The latter were
derived from an OVE and Jtmt cross. All transgenic diabetic mice were easily identified
by a phenotypic marker, which resulted in small eyes, by the intentional co-integration of
the cataract inducing GR19 gene (Liang et al., 2002).
Before sacrifice, mice were weighed and tail tips snipped to procure blood
samples utilized in hemoglobin A1c (HbA1c) and blood glucose analysis. Micromat II
(Bio-Rad, Hercules, CA) kits were utilized for HbA1c measurements. The AlphaTRAK
Blood Glucose Monitoring (test strips and glucose meter) System (Abbott Laboratories,
Chicago, IL) was employed for blood glucose measurements.
All animals were kept in a controlled environment, on a 12-hour light and dark
cycle, at the Biomedical Resources Facility at the University of North Dakota. Cages
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contained natural pine and/or corncob bedding, which was changed routinely. Purina
rodent laboratory chow and water were available to the mice at all times and animals
were maintained according to standards set by the U.S. Department of Agriculture and
the Institutional Animal Care Committee at the University of North Dakota.
Genotyping
The genetic strain of each mouse was confirmed by real-time polymerase chain
reaction (RT-PCR), which identified the presence of the MTII transgene. The genetic
strain identified diabetic and other transgenics from background or control mice. To
extract DNA, approximately 0.5 cm of tail tips were snipped (with sterilized scissors,
washed in 70% EtOH between each sample) and immersed in 100µl of Extraction
Solution (Sigma-Aldrich REDExtract-N-Amp Tissue PCR Kit, Cat. #E7526) in a sterile
500 µl microcentrifuge tube. Twenty-five microliters of Tissue Preparation Solution was
added to each microcentrifuge tube and vortexed thoroughly. Tissue digestion was
carried out by placing the samples in a 55˚C incubator for ten minutes, followed by a
three-minute incubation in a 95˚C water bath. One hundred microliters of Neutralization
Solution B was added to the samples followed by vortexing. The neutralized tissue
extract was then stored at 4˚C until further PCR amplification.
PCR Amplification
To determine the genetic strain of the research animals, PCR amplification was
performed. According to vendor (Sigma-Aldrich) instructions, DNA was extracted from
tail tissue using the REDExtract-N-Amp PCR Reaction Mix (Sigma-Aldrich, Cat.
#R4775) as described above. For each sample, 10 µl of REDExtract-N-Amp PCR
Reaction Mix, forward and reverse primers (50 nmol/ml), and dH2O were brought to a
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final volume of 16 µl. Forward and reverse primers (Invitrogen) targeted the human MTII
gene that was inserted in the Jtmt transgene as described previously (Teiken, 2011). The
MTII forward primer (AATCGGTTGTGGACTGAGGA) and reverse primer
(TCACGGTCAGGGTTGTACAT) generated a 536 bp product and control (FVB) strains
with the forward primer (TCACAATCACCAGGTTTCCAA) and reverse primer
(CAGCCCAGTCAGAAGTCTAAA) generated a 200 bp product (Teiken, 2011).
In a sterile 200 µl microcentrifuge tube, 4 µl of DNA and 16 µl of PCR Reaction
Mix were combined, vortexed, and were then subjected to PCR thermal cycling. The
cycling parameters used were as follows: initial denaturation at 94˚C for three minutes
(one cycle), denaturation at 94˚C for one minute, annealing from 45 to 68˚C for one
minute, and reverse priming at 72˚C for one-two minutes (all three previously described
steps repeated for 30 cycles), and finally tissue extraction at 72˚C for one cycle of ten
minutes. Then samples were loaded directly onto a 1% agarose gel.
Agarose Gel Electrophoresis
Following PCR amplification, 10 µl of amplified DNA was loaded directly into
1% agarose gels. Gels were prepared by adding 0.5 g of agarose (Fischer) to 50 ml of
1xTAE buffer (BIO-RAD), heated at power level 10 for 60 seconds in a General Electric
Turntable Microwave Oven, and gently swirled until all the agarose dissolved. The
solution was cooled for a minute, after which 3.5 µl of 10 mg/ml ethidium bromide
(ETBR) was added. The gel was poured into a casting platform and allowed to set for at
least 20 minutes before samples were added to the wells (formed from the comb inserts
that were placed into the gel during the cooling and solidifying stage). Finally, 1x TAE
buffer was poured onto the gel and 10 µl of the samples were added to each well. The
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samples were run at 80 volts for 40 minutes subjacent to a DNA molecular weight
marker. Gels were viewed using a High Performance Ultraviolet Transilluminator (UVP
–Ultraviolet Products). To process and document images, a Carestream GEL Logic 112
Imaging System was employed.
Quantification of MT in Pulmonary Tissues
Tissue Preparation.
At 110-170 days of age, FVB, Jtmt, OVE and OVEJtmt, animals were deeply
anesthetized by injection of sodium pentobarbital (50 mg/ml, 100 mg/kg body weight).
Upon the absence of limb withdrawal and corneal reflex responses, the abdominal and
thoracic cavities were quickly incised and the right atrium cut to allow for exsanguination
and fluid drainage. Pulmonary tissues were harvested, rinsed in saline, blotted dry, and
weighed. The tissues were then immediately frozen in liquid nitrogen before storage at
-80°C. Tissues were thawed and minced with a razor blade before placing in
ultracentrifuge tubes with 2 ml cold (4°C) 0.1M Tris buffer (pH 10.4). For each mouse
(except the OVE for which only one lung was taken), both lungs were placed in one
ultracentrifuge tube. Tissues were sonically disrupted using a Sonic Dismembrator
(Fisher Scientific) until completely in solution. The tissue suspensions were centrifuged
at 30,000 rpm for 1 hour at 4°C. Supernatants from each sample were collected, vortexed,
aliquoted into 4, 1.5 ml centrifuge tubes and stored at -80°C.
Bradford Assay
The Bradford assay (Bradford, 1976) was used to quantify the amount of total
protein in lungs from all mouse genotypes. For each assay, a standard curve was
generated from a bovine serum albumin (BSA) solution (10 mg/ml; Sigma) diluted in
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0.01M PBS (Sigma) to a range of 120 µg/ml to 5 µg/ml. PBS was used as a blank. Tissue
supernatants were diluted in PBS 1:100, 1:200 and 50 µl of each standard and sample
solution was loaded onto clear polystyrene 96-well plates (Fisher). Bradford reagent
(Bio-Rad) was diluted 1 part reagent to 4 parts dH20 and 150 µl was added to each well.
Color development was read on a SPECTRAmax PLUS microplate spectrophotometer
(Molecular Devices) at a wavelength of 590 nm and the data analyzed by SOFTMax
software.
MT Competitive ELISA Assay
A competitive ELISA developed by Drs. John Swinscoe and Mandy Meyer
(Meyer, 2006) was used to quantify the MT in pulmonary tissues from FVB, Jtmt, OVE
and OVEJtmt mice. For each assay, a Costar EIA/RIA 96-well polystyrene plate (Fisher)
was coated with 50 ng of MTII protein (rabbit liver; Axxora) in 100 µl of 0.1M Tris
(pH 10.4) per well and wells that would serve as blanks received only 0.1M Tris. The
plate was incubated for 6 hrs at room temperature 4°C with slow rotation then washed
3 times with wash buffer (0.01M Tris, 0.02 NaCl, 0.1% Tween 20, pH 7.2). Standard
MTII (1 µg; rabbit liver; Axxora) was polymerized in 3% glutaraldehyde, and
5 µl 0.1M Tris and the tissue sample supernatants were also polymerized in
3% glutaraldehyde on ice for 60-90 min. Metallothionein readings were maximized at
90 min. A primary antibody solution was made by diluting the monoclonal mouse antihorse MTI/II antibody (Dako, Carpentaria) 130 mg/L; Invitrogen) 1:1000 in primary
antibody buffer (0.1M Tris, 0.1% Tween 20, pH 10.4) and kept on ice until use.
After the 90 min incubation on ice, the standard MTII polymerized solution was
diluted to 400µl with 0.1M Tris. A standard curve ranging from 0-10 ng of MTII was
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generated using 16, 12, 8, 4 µl of this standard MTII solution added to 400 µl of the
primary antibody solution. The polymerized sample supernatants were also added to
400 µl of the primary antibody solution at room temperature.
The plate was washed 3 times in wash buffer. Then 100 µl aliquots of standard or
sample solution were added to 4 wells. Half of the blank wells received 100 µl of 0.1M
Tris and the remaining half received 100 µl of primary antibody buffer. The plate was
incubated at 4°C overnight.
The plate was washed in wash buffer 3 times. Then, each well received 100 µl of
alkaline phosphatase conjugated anti-mouse IgG (1:2500 in 0.01M sodium phosphate,
0.02M NaCl, 0.1% Tween 20, pH 7.2; Sigma) and the plate was incubated at room
temperature for 2 hours. The plate was again washed 3 times with wash buffer followed
by a final wash with dH20. Color was developed by the addition of 4-nitrophenyl
phosphate disodium salt (10 mg in 10% diethanolamine, pH 10; Sigma). Color was
allowed to develop for 20-30 minutes. The plate was read on a SPECTRAmax PLUS
microplate spectrophotometer (Molecular Devices) at a wavelength of 405 nm, and the
data analyzed by SOFTMax software.
Metallothionein values were divided by the volume of tissue sample per well to
generate a value as ng/µl that was then adjusted to µg/ml. This value was divided by the
appropriate sample Bradford protein data (µg/ml) to yield the final amount of MT per
sample as µg/mg pulmonary tissue protein.
Vascular Perfusion and Tissue Preparation for Microtomy
In an effort to prepare excellent samples for immunohistochemical (IHC) or
morphometric analysis, animals were sacrificed by vascular perfusion through the left
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ventricle. Prior to perfusion, mice were anesthetized by intraperitoneal (IP) injection of
sodium pentobarbital (100 mg/kg). Limb and eye reflexes to sensory stimulation were
checked prior to any incisions, ensuring that the animals were deeply anesthetized.
Micro-surgical scissors were used to incise the right atrium, to allow fluid drainage and
exsanguination. Immediately following the incision, a 26G 3/8” hypodermic needle (B-D
& Co., Rutherford, NJ), attached to plastic medical grade 0.020 inch tubing was inserted
into the left ventricle for infusion of 50 ml warm isotonic (0.9M) saline and additional
perfusates to clear the vascular bed. Flow rates for saline and fixatives were set at
approximately 6 ml/min. At the time of perfusion, several organs including the lung,
heart, kidneys, and retinas were harvested to prepare an adequate diversity of tissue
sample. Perfusion was deemed adequate when eyes, lips, and tail of the mouse became
pale and limbs were rigid.
Perfusion Using Zamboni’s Fixative
Tissue samples prepared for IHC analysis were perfused and fixed with
Zamboni’s (Zamboni and Stefanini, 1968) fixative. This fluid was prepared by dissolving
4 g of paraformaldehyde in 25 ml of distilled water heated to 50˚C. Twenty ml of 0.5M
sodium phosphate buffer and 16.5 ml picric acid were added to the solution, which was
then stirred, cooled to room temperature, and filtered. The solution was brought to a final
pH of 7.4 by drop wise addition of 1N sodium hydroxide (NaOH) or 1N hydrochloric
acid (HCl). The fixative was brought to a total volume 100 ml by adding 38.5 mL of
dH2O.
Prior to perfusion, animals were anesthetized as described above. Perfusion was
initiated with 50 mls of filtered prefixative (0.9% NaCl, 0.1% NaNO2, and 100 units of
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heparin in dH2O) administered at a rate of 6-7 ml/min, followed by 100 mls of full
strength Zamboni’s fixative. Immediately following perfusion, pulmonary tissue was
surgically removed and immersed in cold Zamboni’s fixative for three hours. Tissues
were stored in 25% sucrose buffer (sucrose, glycerol, 0.5M phosphate buffer, 1% sodium
azide in dH2O) at 4˚C overnight before embedding in paraffin.
Perfusion Using PIPES Fixative
All animals were adequately anesthetized and perfusion was initiated as
previously described. For preparation of tissue samples for TEM observation and TEM
morphometry, glutaraldehyde-based PIPES fixative (Bauer and Stacey, 1977) was
employed. PIPES fixative was freshly prepared for each perfusion procedure. The
fixative consisted of PIPES buffer (PIPES {Piperazine-N,N’-bis[2-ethanesulfonic acid]}
(Sigma: P8203-250G), 1N NaOH, distilled water), and 20% dextran (Sigma: D4626),
10% paraformaldehyde, and TEM grade glutaraldehyde 10% (Tousimis, #1060A).
Following observation of clear fluid drainage from the right atrium, 20 ml of warm
fixative and then 40 ml of cold fixative was administered. Organs harvested from mice
were immediately immersed in vials of cold PIPES fixative for approximately
30 minutes.
Tissues were minced to 1 𝑚𝑚3 blocks and placed in cold fixative for three hours

and then washed in PIPES buffer with 2% sucrose for 30 minutes, at room temperature.
Blocks were then immersed in a 1:1 solution of 2% osmium (OsO4) (Stevens
Metallurgical Corp., NY, NY), 3% potassium ferricyanide (K3Fe(CN)6 and distilled

water in PIPES buffer with one part PIPES buffer, 6% (sodium iodate) NaIO3 (Fisher Cat
# 5322-100 P.259C) and 4% sucrose overnight. Following overnight treatment with
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buffered OsO4, tissue samples were dehydrated in an ascending series of alcohols as
follows: two five-minute treatments with 15% ethanol (EtOH), two ten-minute treatments
with 30% EtOH, two 15 minute treatments with 50% and 70% EtOH, three 20-minute
treatments with absolute EtOH, and finally, two one-hour washes in absolute EtOH.
Following dehydration, tissues were rinsed briefly in propylene oxide (1,2 epoxy
propane), followed by two additional 15-minute propylene oxide washes, and a 1:1
solution of epoxy resin and propylene oxide. The epoxy resin consisted of Araldite 502 –
Modified Bisphenol A Epoxy (EMS, Cat. #10900), EMbed-812 (Epon-812 Substitute)
(EMS, Cat. #14900), Dodecenyl Succinic Anhydride (DDSA) (EMS, Cat. #13710), and
2,4,6,-{Tri(Dimethylaminoethylphenol} (DMP-30) (EMS, Cat. #13600).
The final step in tissue preparation included an overnight incubation in a 3:1
solution of epoxy resin and propylene oxide before an 18-hour incubation in full strength
epoxy resin. All tissues were then embedded in fresh epoxy resin and incubated at 65˚C
for at least 72 hours.
Paraffin Embedding
Tissues perfused with Zamboni’s fixative were embedded in paraffin for
immunohistochemical analysis by light microscopy. Tissue dehydration was carried out
in a series of graded alcohols, beginning with 50% EtOH for 30 minutes, followed by
70%, 80%, 95%, and 100% EtOH for 30 minutes each (repeated twice). Tissues were
then immersed in two washes of CitroSolv (Fisher) for 20 and 30 minutes followed by
60 minutes in a 1:1 Paraplast (Fisher):CitroSolv solution, and two 60-minute rounds in
full-strength Paraplast in a vacuum oven at 60˚C. Pulmonary tissue was embedded in
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plastic molds using a cooling table on a paraffin embedding apparatus. Tissues were
maintained at -20˚C for at least 24 hours prior to sectioning.
Immunohistochemistry
For IHC analysis, paraffin blocks were trimmed with tEM single-edge stainless
razor blades (Tousimis #7250) to form a pyramidal shape face. Blocks were then placed
in a Leica RM2125 microtome and sections of tissue were cut at approximately 5-7 µm
with a biological grade steel knife. Ribbons of tissue serial sections were placed in a
water bath (40˚C TissuePrep). Sections were collected on glass slides coated with poly
L-lysine (Histology Control Systems, Glen Head, NY). Slides were stored at 4˚C until
they were used for IHC procedures.
A Tissue-Tek® Slide Staining Set (Electron Microscopy Services) was used to
immerse slides in CitroSolv for paraffin removal. This was repeated three times for five
minutes per immersion, followed by subsequent rehydration in a series of graded alcohols
(70%, 95%, and 100% EtOH three times for 5 minutes). Slides were then rinsed for five
minutes in gently running cold tap water. A liquid blocker PAP-pen (EMS, Cat. #71310)
was used to encircle the tissue on slides after the five-minute water bath, and the slides
were placed in a humidifying chamber with 3% hydrogen peroxide (H2O2) for one hour.
Next, slides were subjected to 10% normal rabbit serum for 20 minutes and then mouseto-mouse blocking reagent (Scytek) for 30 minutes. After a one-hour incubation in 1%
Blocking Reagent (Invitrogen) [10mg/ml in 0.01M PBS (Sigma)], slides incubated for
one hour in primary antibody, at a 1:100 dilution (in 1% Blocking Reagent). The MT
primary antibody (mouse anti-horse MTI/II, Dako) was administered to positive controls
(renal tissues from animals overexpressing endothelial MT (Teiken, 2011)), while the
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same tissue treated with 1% Blocking Reagent only served as negative controls. Slides
were then rinsed three times in 0.01M PBS, then treated one hour with biotinylated rabbit
anti-mouse IgG (Invitrogen) at a 1:200 dilution in 1% Blocking Reagent.
Following three rinses in 0.01M PBS, slides were treated in a humidifying
chamber with Horse Radish Peroxidase (HRP) conjugated streptavidin (Invitrogen) at a
dilution of 1:500 in 1% Blocking Reagent. All slides were then exposed to a 1:10 solution
of 3,3’-Diaminobenzidine (DAB) in 0.01M PBS and a 1:1000 solution of 30% H2O2. A
final rinse in cold tap water preceded a nuclear counter stain with 0.5% methyl green on
low heat. Slides were allowed to dry overnight prior to the addition of Permount attached
cover slips and observed by bright field light microscopy.
Microtomy
Epoxy blocks containing pulmonary tissue were trimmed to form a trapezoid face
with a 1 mm base with tEM single-edge stainless razor blades. An MTX ultramicrotome
equipped with a gem grade diamond knife (DiATOME) and an MTX ultramicrotome was
utilized for making thick and thin tissue sections. First, thick sections (250 nm) of tissue
were made and examined by light microscopy to identify tissue location and position.
Thick tissue sections were collected on a drop of dH2O on a glass slide and were dried on
low heat. Slides were stained with 1% toluidine blue in 1% sodium borate, and following
the addition of cover slips were examined by bright field (Olympus BH-2) microscopy.
When ultramicrotomy was deemed appropriate, thin sections (70 nm) were cut
and ribbons of tissue sections were collected in a dH2O metal trough. A cotton swab
dipped in chloroform was passed over the sections to eliminate wrinkles within the tissue.
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Ribbons of tissue, with an optimal interference color of silver, were collected on 300 μm
mesh naked copper grids.
Light microscopy
Glass slides stained with 1% toluidine blue or immunohistochemically, as
described above, were viewed on a brightfield Olympus BHS (BH-2) light microscope.
An Olympus 63x and 100x oil immersion objective lenses were used to view any
pathological features of pulmonary tissue. Images were captured using a SPOT Idea
Digital Microscope Camera and SPOT imaging software version 4.6 (Diagnostic
Instruments, Inc.).
Staining procedure for TEM grids
Tissue samples for TEM on copper grids were stained with 2% uranyl acetate and
lead citrate (Venable and Coggeshall, 1965). Uranyl acetate was prepared by dissolving
0.4 grams of uranyl acetate in 10 ml of distilled water. A one to one solution of 4%
uranyl acetate was made with absolute EtOH, followed by filtration through a 0.2 μm
filter (Thermo Scientific, Cat. No. 190-2520). Grids were stained for five minutes on
silicone mats (PELCO®, #10521) in petri dishes covered with aluminum foil for
protection from photon exposure. Grids were rinsed with distilled water before staining
with lead citrate. Initially, 0.6 grams of lead citrate was mixed in 20 mls of boiled water,
followed by the drop-wise addition of 10N sodium hydroxide to clear the solution
(Venable and Coggeshall, 1965). The lead solution was then centrifuged for 15 minutes.
The staining procedure was repeated, leaving grids on the silicone mats for 5 minutes in
covered petri dishes lined with NaOH pellets to protect grids from CO2 exposure. Grids
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were then rinsed thoroughly in distilled water and allowed to dry for a minimum of
24 hours in grid storage boxes.
Transmission Electron Microscopy
Thin sections of pulmonary tissues were photographed in a Hitachi 7500 TEM at
an initial magnification of x30,000. Ten micrographs were obtained from each tissue
block (two blocks per mouse), totaling at least 240 micrographs for each mouse
genotype. Micrographic films (Kodak 4489) were developed by conventional methods,
scanned (Epson Perfection V750 Pro scanner), and printed (HP LaserJet P2015 printer)
on plain 8.5”x11” paper. Prior to printing, each micrograph was magnified by exactly
2.8X (Adobe Photoshop) to guarantee a final magnification of precisely x84,000. This
relatively high magnification was chosen to ensure accurate marking of PABMs on
finished prints.
Random perpendicular widths of the PABM were marked utilizing a transparent
grid overlay (three cm squares) placed onto each micrograph. This established true
randomization in marking PABMs. Only points of PABM that intersected the grid were
marked for measurement. Accordingly, all points along the PABM were equally likely to
be selected and operator choice was not an option.
Unbiased TEM Morphometry
As mentioned above, operator bias in PABM measurement was eliminated and
measurement consistency was maintained with the use of a transparent grid overlay. In
pulmonary tissue, the inner plasma membrane of the endothelial cell (of the blood-air
barrier) was used as a reference for the starting point of measurements. Where alveolar
cells crossed the superimposed grid, a mark is made at the point of PABM intersection.
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By the orthogonal intercept method (Jensen et al., 1979), a diagonal line was
drawn across the PABM from the beginning reference point on the endothelial cell to the
plasma membrane of the perpendicularly located alveolar cell. Using a digitizing tablet
and specialized software (Bioquant, R and M Biometrics, Inc.), the length of the
perpendicular lines (orthogonal intercepts) were measured and distributed into one of
nine classes of thickness (Hirose et al., 1982). The harmonic mean apparent thickness
(Dische, 1992) of the measurements was then calculated and multiplied by 8/3π (Jensen
et al., 1979) to eliminate an expected right-sided skew of the numerical distribution and
to give the true PABM width (Gundersen and Osterby, 1973).
At least ten images were taken of each block, which allowed for the analysis of at
least 120 micrographs per mouse. On average, one micrograph provided approximately
ten PABM measurements. Taken together, this resulted in > 485 micrographs measured
in the 60 day-old group, and approximately 4,000 PABM measurements available to
calculate harmonic means (Table 3). The 150 day-old cohort showed similar averages for
blocks per mouse, micrographs obtained per block, and average number of PABM
measurements per micrograph. Accordingly, the total number of PABM measurements
used to calculate the harmonic means in the 150 day-old group was ~4,400.
Statistics
Distributions of “true” PABM thickness [as derived from orthogonal intercepts on
sets of at least 20 micrographs for each animal type (FVB, Jtmt, OVE and OVEJtmt)]
were statistically compared using the nonparametric Wilcoxon-Mann-Whitney rank-sum
test as previously described (Carlson et al., 2003, 2004). Significance value for all tests
was set at P≤0.05.
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CHAPTER III
RESULTS
General Condition of Animals
In general, 60 day-old FVB and Jtmt mice are physically active, exhibit sleek and
shiny coats, and are approximately of equal size (Figure 1A). The diabetic animals (OVE
and OVEJtmt mice) also demonstrate active behaviors at 60 days. However, their coats
are noticeably less sleek and appear patchy. All diabetics, including OVE and OVEJtmt
mice are recognizable by their small eyes (Figure 1B), but otherwise cannot be
distinguished from each other. No other obvious physical characteristics are different
among the four genotypes.
Likewise, at 150 days of age, FVB and Jtmt mice are physically indistinguishable
and maintain healthy body weights, sleek coats, and active physical dispositions.
However, their diabetic counterparts are easily identifiable as they not only exhibit small
eyes, but their coats are generally patchier and dull. Diabetic mice also tend to be
somewhat lethargic and weigh less than Jtmt mice (Table 2). Glycated hemoglobin levels
in OVE and OVEJtmt mice are consistently higher than FVB and Jtmt mice (Table 2).
Fasting blood glucose measurements are consistent with HbA1c data and also are
decidedly higher in the diabetics than FVB and Jtmt mice (Table 2).
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Pulmonary Morphology
Light Microscopy
Light microscopic images of toluidine blue stained thick sections of pulmonary
tissue from 150 day-old mice (Figure 2A) show typical textbook features of respiratory
tissue. By this technique the terminal portion of the respiratory system can be visualized.
This region contains terminal bronchioles, respiratory bronchioles, alveolar ducts,
alveolar sacs, and individual alveoli. However, only alveolar ducts, alveolar sacs, and
alveoli are seen by conventional toluidine blue staining (Figure 2A). Alveolar ducts are
surrounded by pockets of alveolar sacs that terminate in individual alveoli. The latter are
separated from each another by alveolar septa. Small veins also can be seen in cross
section, with occasional intravascular erythrocytes. Individual components of alveolar
walls cannot be identified at the LM level, but the thin respiratory filtration barrier can
still be appreciated. Type I alveolar cells are the most common cell type contributing to
the large surface area for gaseous exchange. This extensive layer is manifested
morphologically as an external attenuated cytoplasm of the respiratory filtration barrier.
Transmission Electron Microscopy
Components of the respiratory tissue in 150 day-old FVB mice that are not
identifiable at the LM level, are clearly resolved by TEM. The small rectangular area
drawn in the large original LM image (Figure 2A) illustrates the approximate size of the
area shown in the TEM inset at the bottom of the figure (Figure 2B). The inset TEM
image (Figure 2B) illustrates structures that could be expected to be found included in the
small rectangle in Figure 2A at an original magnification of approximately 100x. Type II
alveolar cells are located in the inter-alveolar septa where they offer structural support to
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surrounding alveolar and capillary networks. Circulating lymphocytes and erythrocytes
occasionally occupy capillary spaces. Structural components of the respiratory filtration
barrier, such as the meshwork of elastin and collagen that lies within the extracellular
space, can usually be found in the alveolar septa. Intracellular structures in type II
alveolar cells (e.g. nuclei and lysosomes) can be identified by low magnification TEM
(Figure 2B).
Increasing the TEM magnification to 16,000 diameters offers a sharper resolution
and the PABM appears as an electron dense structure surrounding alveoli, though the
PABM still is not easily measured for data collection and analysis (Figure 3). Bundles of
elastin are also more apparent at this magnification. They are often located in the
structural matrix between A1 and A2 cells, (located in the upper right corner of the
Figure 3). Endothelial cells line the capillary space and are present on the intravascular
side of the PABM. Alveolar type I cells line the air space on the opposite side of the
PABM. Other interesting features include endothelial flaps that are identifiable where
endothelial cells come together to form tight junctions.
Increasing to an even higher magnification of 60,000 diameters (Figure 4)
demonstrates individual components of the respiratory filtration barrier and allows for
consistent, accurate, and unbiased PABM measurement and data collection. The
cytoplasm of the thin endothelial cells line the internal side of the blood-air barrier, and is
separated from the alveolar epithelium by the PABM. Endothelial cells are orientated
toward the left and right external side of the filtration barriers in Figure 4. Type I alveolar
cells line the air space and are located toward the middle of the micrograph. Between the
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two cell layers, the PABM runs the length of the micrograph in a superior to inferior
direction.
At the LM level, individual PABMs are not recognizable or measureable.
Accordingly, in the current study TEM is required to clearly and reliably identify the
limits of the PABM of the lung. Four groups of mice are utilized to study the PABM, and
at 60 days of age, and a magnification of 60,000 diameters, variations in PABM thickness
between genotypes can be appreciated (Figure 5). The PABM of each mouse genotype is
illustrated by the opposing arrowheads and are ordered as follows; 60 day-old FVB
PABM (Figure 5A), 60 day-old Jtmt PABM (Figure 5B), 60 day-old OVE PABM
(Figure 5C), and 60 day-old OVEJtmt PABM (Figure 5D). In Figures 5 A-D, endothelial
cells are much thinner than type I alveolar cells. This structural characteristic is an
excellent aid in discriminating between capillary and alveolar components of the
respiratory filtration barrier. Endothelial cells in each image in Figure 5 are positioned
toward the superior portion of the micrograph (as indicated in Figure 5D), and the A1
cells face the inferior portion of the PABMs in Figures 5 A-D. Generally, the capillary
endothelium lines the concave side of the PABM and type I alveolar cells form its convex
border.
Micrographs of 150 day-old lung tissue show morphological features remarkably
similar to those obtained at 60 days of age. By visual inspection, the PABM of 150 dayold FVB mice (Figure 6A) appears considerably thinner than PABMs from Jtmt
(Figure 6B), OVE (Figure 6C), and OVEJtmt (Figure 6D). Significantly, the 150 day-old
OVE (Figure 6C) PABM is appreciably thicker than the other age-matched PABMs in
Figure 6. Similar to observations in the 60 day-old lungs, the endothelial cells are much
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thinner compared to their type I alveolar cell counterparts, and are orientated in the same
manner as previously described.
Pulmonary Alveolar Basement Membrane (PABM) Morphometry
Interestingly, PABM measurements obtained in the 60-day group generate
harmonic means within a very small range (Figure 7) shown as the PABM thickness of
FVB, Jtmt, and OVE mice all approach 50.0 nm. These data affirm our preliminary visual
observations of these PABMs, which suggest that they are relatively similar in width.
Statistical significance value is set at P < 0.05.
As anticipated, the greater PABM thickness differences noted by preliminary
visual observation in 150 day-old mice relative to 60 day-old animals is confirmed by
orthogonal intercept analysis (Figure 8). Not surprisingly, the OVE genotype exhibited
the thickest PABM measurements. Moreover, the largest margin of difference between
any two genotypes was the interval between 150 day-old OVE and OVEJtmt mice. The
nonparametric Wilcoxon-Mann-Whitney rank-sum test indicated statistical significance
between PABM thicknesses in the FVB and OVE groups (P = 0.020), Jtmt and OVEJtmt
groups P = 0.0095), and OVE and OVEJtmt groups (P = 0.012) at 150 days of age.
Statistical significance value is set at P < 0.05.
When both age groups are analyzed together, statistically significant differences
were observed between the 60 day-old OVE and 150 day-old OVE genotypes (Figure 9).
However, this significant difference is completely eliminated when OVEJtmt mice in the
two age groups are compared. Interestingly, FVB mice show no significant changes in
PABM width with age. (Figure 9). Significantly, 150 day-old Jtmt PABMs average
~52.76 nm, a 5.4% thickness increase over 60 day-old mice of the same group. At 150
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days, PABMs in OVEJtmt mice are increased by 6.1% over 60 day-old mice (~47.75 nm
compared to ~44.97 nm) while OVE mice show the largest age-related PABM width
increase, an average of ~51.49 nm compared to ~58.42 nm, or approximately 18.3%.
When compared to age matched controls, 150 day-old mice exhibit diabetesinduced PABM thickening in the OVE group (~58.42 nm) but more importantly; a
significantly (P = 0.012) reduced PABM width is demonstrated in OVEJtmt mice
(~47.75 nm). Also, FVB mice show levels of thickening similar to the Jtmt group with
averages of ~48.71 nm and ~52.76 nm, respectively (Figure 9A).
Analysis of MTI/II Expression
Immunohistochemical Analysis of MTI/II in 150-Day Lung Tissue.
To identify the expression of MT I/II in endothelial cells of the lung, IHC analysis
was utilized. Positive controls from Jtmt mice were obtained from the kidney (Figure
10B) and were treated with primary antibody as previously described. Negative controls
were derived from the same tissue. However, these samples were not exposed to primary
antibody and received blocking reagent in its place. As expected, the positive controls
showed light brown staining of the MT I/II antibody in the endothelium. Negative
controls indicated no MT I/II staining.
Positive staining for MT I/II in the endothelium of the lung was also visible
(Figure 10D and F). Lungs from Jtmt and OVEJtmt showed positive expression of MT
I/II as indicated by light brown staining around the endothelium of small veins.
Immunohistochemical staining indicated that MT I/II was expressed in the pulmonary
vasculature of the transgenic mouse lines, which suggested quantification of MT I/II
could be executed.
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Competitive ELISA of MTI/II in 150-Day Lung Tissue
At 150 days of age, lungs from an FVB, OVE, Jtmt, and OVEJtmt mouse were
obtained to quantify MT I/II present in pulmonary tissue by the competitive ELISA
method. Metallothionein levels were expressed per total μg of protein in each tissue
sample. Levels of MT I/II in each genotype were as follows: FVB (0.23 μg/mg), OVE
(0.22 μg/mg), Jtmt (0.45 μg/mg), and OVEJtmt (0.33 μg/mg). Importantly, the Jtmt lung
measured MT I/II two times the amount found in the FVB control. The OVEJtmt
pulmonary tissue also measured higher MT I/II protein levels than the controls, but were
not as elevated to the levels of the Jtmt pulmonary tissue. Data obtained from this method
was remarkably consistent with the staining patterns found in IHC analyses of the same
tissue.
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CHAPTER IV
DISCUSSION
Basement membrane thickening was identified in diabetic patients more than
50 years ago and has long been considered the morphological hallmark of the disease
(Bergstrand and Bucht, 1959). Early studies on the effects of DM on BMs indicated
changes in protein composition in diabetic mice compared to healthy controls (Rohrbach
and Martin, 1982). Laminin and collagen IV synthesis was induced in diabetic mice,
although the synthesis of proteoglycans was inhibited in these same animals. Treating
diabetic mice with insulin returned the synthesis of proteoglycans to normal levels over
time, suggesting that the lack of heparan sulfate proteoglycan stimulated the
overproduction of laminin and collagen IV in an effort by cells to compensate for the loss
of proteoglycan synthesis leading to decreased BM turnover and increased BM width
(Rohrbach and Martin, 1982).
More recent studies on diabetic animals have suggested that although expression
of some ECM proteins is increased, it is not clear that such synthesis is the result of
compensatory hypertrophy. In fact, it is apparent that BM thickening in most diabetic
models is due largely to the lack of breakdown and turnover of matricellular molecules,
and not an overexpression of various ECM proteins (Tsillibary, 2003).
Although the mechanisms leading to increased BM width have been elusive, as
pointed out in the Introduction, considerable progress has been made in unpacking the
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potential regulatory pathways leading to decreased ECM turnover in DM. Recently, an
interesting unifying hypothesis was offered (Brownlee, 2001) that suggested that in the
hyperglycemic state, oxidative stress, mainly derived from mitochondrial activity,
generated high levels of free radicals (small charged oxygen ions), capable of
considerable tissue damage. Moreover, numerous studies aimed at reducing the mass of
free radicals have reported remarkable mitigation of a variety of chronic diabetic
complications in the kidney and heart, (Carlson et al., 2013; Velic et al., 2013).
A review of the literature shows that attempts to link DM and pulmonary structure
and function have been sparse, inconsistent and contradictory. Basement membrane
thickening in the lung has been reported in several pulmonary pathologies, but has not
been correlated directly with DM. Typically BM thickening has been identified in other
diseases, including asthma, chronic obstructive pulmonary disease, tuberculosis, and lung
cancer (Watanabe, 1997). However, BM thickening in these studies focused primarily on
bronchiolar BMs and cannot be compared to PABMs, where the majority of gas
exchange occurs.
It must also be pointed out that diabetes-related research has not focused on
pulmonary tissues because of the high probability that extant clinical complications may
be masked by more serious manifestations, including kidney failure. Nevertheless, a few
studies (Vracko, ’79; Kida et al., ’83; Fuso et al.,’96) have given some attention to the
diabetic lung and suggest that pulmonary tissues may be somewhat affected by the
disease.
In 1979, Vracko utilized post mortem tissue from human diabetics in a TEM
analysis of alveolar and pulmonary capillary basement membrane thickening of diabetic
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patients. Unfortunately, the PABM thickening data was not measured at the points where
alveolar and endothelial BMs fuse to form the PABM. Additionally, the data was not
correlated with the duration of the disease, or with the age of the patient.
A later study (Kida et al., 1983) centered on the volume proportion of the alveolar
wall, reported a 24% increase in streptozotocin-induced diabetic rats, though the data was
not statistically significant. On the other hand, these investigators demonstrated a
significant increase in the number of alveoli (per unit volume) in diabetic rats compared
to normal controls, as well as an increase in surface to volume ratio (Kida et al., 1983).
However, a direct correlation between DM and these changes could not be shown
because the effect of insulin treatment was not studied. Accordingly, potential side effects
of streptozotocin (a nephrotoxin and possible pulmonotoxin) on the lung could not be
ignored (Ofulue et al., 1988).
Furthermore, it has been speculated that diabetic patients, specifically Type I
diabetics, have a decreased capillary blood volume and carbon monoxide diffusing
capacity (Fuso et al., 1996). However, published results on this subject are conflicting
(Fuso et al., 1996). Contradictory data reported in studies measuring diffusing capacity
and capillary blood volume, were likely due to differences in the manner in which
patients were tested (e.g. supine vs. sitting). It is well known that variations in testing
parameters (including body position in pulmonary function tests) alters the functional
recruitment of superior pulmonary lobe capillaries as well as the specificity and
sensitivity of these tests (Fuso et al., 1996).
Accurate histological descriptions of pulmonary alveoli demonstrate a threelayered structure including an external layer of alveolar cells, and an internal layer of
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endothelial cells both of which lie immediately subjacent to the central PABM (Cross and
Mercer, 1993). In vertebrate animals, this tripartite morphological pattern is repeated only
in the urinary filtration barrier of the kidney where the GBM is lined internally by
glomerular podocytes and externally by fenestrated endothelium. To be complete, the
choroid plexuses located in the ventricles of the brain exhibit some structural similarities
but only in the lung and kidney are two BMs truly fused to form a single PABM or GBM
that serves as a passive (though size-selective and charge-selective) filter.
Despite patient compliance and rigid insulin injection schedules, increased GBM
width is widely recognized as a diagnostic feature of both Type I and Type II DM.
Interestingly, its pulmonary counterpart is rarely mentioned and has received little
morphometric investigatory activity.
Accordingly, the current investigation was designed to follow up on a single
preliminary study by Carlson et al., (2003) that showed that although not all varieties of
BMs are subject to significant diabetic thickening, the GBM and several other types,
including PABM, were remarkably vulnerable to thickening in severely diabetic OVE
mice.
The present study was patterned after a remarkable investigation (Zheng et al.,
2008) that reported severely diabetic (OVE) mice were protected against albuminuria and
several other diabetic parameters by crossing them with transgenic mice with specifically
targeted antioxidants (MT), particularly powerful scavengers of free radicals injurious
ions widely suspected to mediate tissue damage in most chronic complications of DM. In
fact, the ROS scavenging activity of MT has been shown to be greater than 50 times
more effective than GSH (Sato and Bremner, 1993).
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These studies motivated co-workers in the Carlson laboratory (University of
North Dakota School of Medicine and Health Sciences) to investigate the efficacy of MT
in ameliorating diabetic complications, including BM thickening, in the heart (Velic et
al., 2013), kidney (Carlson et al., 2013), and pancreas utilizing unbiased TEM
morphometry (Chen et al., 2001). The results of these studies were universally positive
and in each case, breeding OVE diabetic animals to specific MT overexpressors (Nmt,
glomerular podocytes; MT, cardiomyocytes), BMs of subjacent microvascular cells in the
diabetic animals were significantly protected from reaching the widths of untreated
diabetic mice.
These results concerted efforts to generate a strain of mice in which the effect of
MT overexpression could be evaluated more globally. Therefore in 2011, Teiken utilized
the Tie2 promoter and the MT II isoform to generate a plasmid that could be used to
develop a transgenic mouse that overexpressed MT specifically and ubiquitously in
endothelial cells.
Importantly, immunohistochemical analysis confirmed that MT is widely
expressed in Jtmt endothelial cells and although the very small and delicate nature of the
respiratory filtration barrier (particularly the < 2 µm thick pulmonary endothelium)
reduced the visualization quality of MT in this layer, preliminary results from the more
sensitive competitive ELISA technique is encouraging. This method suggested that
pulmonary endothelial cells from Jtmt mice carry at least a 2 fold increase in MT
compared to FVB controls. These data strongly supported our claim that the human MT
I/II transgene was successfully overexpressed in the endothelial cells of transgenic mice
(Teiken, 2011).
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The new mouse (called Jtmt) was successfully developed and is a remarkably
effective model for mitigating BM thickening by crossing it with diabetic mice. In this
regard it has been shown to completely eliminate hyperglycemia-driven GBM and
myocardial capillary BM thickening, and it was the only known experimental protocol to
fully mitigate diabetic BM thickening.
In light of preliminary studies showing that PABM was one of only a few BMs
that are significantly widened in the diabetic OVE mouse (Carlson et al., 2003), the
current Jtmt study utilized unbiased TEM morphometry to test my working hypothesis.
The overall paradigm was designed to determine whether diabetes-induced oxidative
stress might be a major factor in any possible PABM increased width, and secondly to
determine the effect of MT overexpression in endothelial cells on PABM thickness.
The severely diabetic OVE mouse (Epstein et al., 1989) was chosen for the
experimental model because early studies using this model of type I DM showed
significant BM thickening in a wide variety of tissues including kidney (glomerulus),
heart (myocardial capillaries), retina (choroid), lung, and peripheral nerves (Carlson et
al., 2003, 2004, 2013). Although the lungs have not previously been implicated in
chronic complications of DM, its highly vascularized parenchyma and potential for
extensive oxidative damage warranted further study into potential hyperglycemia-driven
PABM thickening.
To our knowledge, the current study was the first to report carefully applied
morphometric methods to show PABM thickening in transgenic diabetic animals, and it
was clearly the first to show that overexpression of MT in endothelial cells mitigated
hyperglycemia-induced PABM thickening. Using a transgenic mouse line, we were able
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to study DM in a remarkably long-living animal model (Carlson et al., 2013) that exhibits
a plethora of pathophysiological features similar to those found in humans (Teiken et al.,
2011). In addition, this model avoided any adverse effects of inducing diabetes in animals
by the use of semi-toxic pharmaceutical drugs (e.g. streptozotcin) that may have serious
side effects.
Our studies indicated that at 60 days of age, no significant differences were
evident between PABM thickness in FVB, Jtmt and OVE, while OVEJtmt showed mildly
thinner PABMs. This was undoubtedly due to the youth and immaturity of the mice when
diabetes-induced complications were not manifested. Not surprisingly, light microscopy
and TEM morphometric analysis showed no fundamental changes between the diabetic
genotypes versus healthy controls. Additionally, a thorough investigation of BM
thickness increases in other tissues at 60 days of age would be necessary to determine the
approximate age of onset of vascular complications in diabetic mice.
On the contrary, at 150 days changes in PABM thickness between diabetic and
healthy control mice were measurable and significant. Interestingly, the OVEJtmt
bitransgenic mice showed a significantly reduced PABM thickening compared to the
OVE and FVB lines. These data strongly supported the existing considerable evidence
that ROS may be a primary cause for DM-induced BM thickening in various tissues, and
that antioxidants, specifically MT, were effective scavengers of circulating free radicals
in affected tissues.
In summary, data in the current study strongly support the working hypothesis of
the current study that 1) PABMs exhibit DM-related thickening in severely diabetic mice
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and 2) that this structural alteration is mitigated by specific endothelial targeted
expression of MT.
These results offer much more than merely interesting data, and they clearly
exhibit more than yet another instance of diabetic BM thickening. Because historically
the lungs have not presented major clinical challenges in DM, experimental designs
based on this organ have been largely ignored. As a consequence, the concept of diabetic
pulmonopathy as one of the major chronic complications of DM has not reached the level
of current conventional wisdom. Nevertheless, data in the current study provide
unequivocal evidence that at 150 days of age, hyperglycemia-driven oxidative stress
leads to statistically significant increased true width (+20%) of PABM in severely
diabetic transgenic mice. More importantly, the study demonstrates that antioxidants
specifically targeted to the global endothelial cell population completely eliminates
hyperglycemia-driven PABM thickening and returns their width to below onset control
levels. This is astonishing and places the PABM in a class of elite BMs including
glomerular and myocardical capillary BMs that are reduced to normal width and respond
positively to endothelial antioxidant therapy (Hewitt et al., abstract in press).
It is concluded that the current study provides a previously unknown baseline of
morphometric information on PABM widths in control and severely diabetic transgenic
mice and establishes a definition of diabetic pulmonopathy as a new and innovative
chronic complication of diabetes. Moreover our preliminary data demonstrates the
efficacy of antioxidant therapy on this disease and offers hope for translational studies by
which this therapeutic modality can become a model for the reduction of the devastating
consequences of many if not, all chronic complications of DM issues.
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APPENDIX

Table 1. Animal genotype, number of animals, number of epoxy blocks sectioned,
number of micrographs taken, and number of measurements made per micrograph for
orthogonal intercept calculation of true PABM thickness.
Genotype
Total # of
Average # of
Total # of
Number Total # of
Micrographs
PABM
PABM
of
Blocks
measurements
measurements
Animals
per micrograph
60 Day-Old Mice
FVB
6
12
120
7.49
899
OVE
6
12
129
7.78
1,004
Jtmt
6
12
118
8.58
1,013
OVEJtmt
6
11
118
8.79
1,038
TOTAL
24
47
485
8.15
3,954
150 Day-Old Mice
FVB
6
12
120
9.7
1,165
OVE
4
8
80
11.2
896
Jtmt
7
14
137
8.75
1,199
OVEJtmt
6
12
120
9.24
1,109
TOTAL
23
46
457
9.56
4,369
Numerical data derived from micrographs of 60 and 150 day-old mice, listed by genotype
with the number of animals used for each group, as well as the total number of blocks
sectioned, total number of micrographs taken, and the average number of measurements
per micrograph. The final column lists the total number of micrographs obtained for each
genotype.
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Figure 1.

General appearance of 150 day-old mice.
A) Representative normal (FVB) mouse. FVB and transgenic (Jtmt)
normal animals similar to this mouse can be identified by the presence of
normal eyes.
B) Representative diabetic (OVE) mouse. OVE and bi-transgenic
(OVEJtmt) diabetic mice consistently exhibit small eyes as illustrated.

Table 2. Mean body weight, blood glucose, and HbA1c values from 60 and 150 day-old
FVB, Jtmt, OVE and OVEJtmt mice ± S.D.
Genotype
Age (days)
Body Wt (g)
Blood Glucose
HbA1c (%)
(mgs/dl)
FVB
60
21.78 ± 1.69
192.83 ± 21.95
4.30 ± 0.01
FVB
150
34.80 ± 3.96
198.80 ± 21.71
4.06 ± 0.08
Jtmt
60
27.21 ± 3.74
194.00 ± 38.59
4.20
Jtmt
150
28.47 ± 2.86
188.28 ± 31.06 <4.0
OVE
60
22.87 ± 1.77
644.66 ± 64.19
8.65 ± 0.74
OVE
150
29.97 ± 2.81
715.50 ± 49.00
10.40 ± 1.43
OVEJtmt
60
20.96 ± 1.80
610.16 ± 68.16
8.50 ± 1.04
OVEJtmt
150
25.25 ± 0.69
634.16 ± 86.06
9.68 ± 1.04
60 and 150 day-old mice listed by genotype and with their associated body weights
(measured in grams), blood glucose levels (measured in mg/dl), and HbA1c levels
(represented by percentages).
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Figure 2.

Toluidine blue stained light micrograph with higher magnification
transmission electron micrograph inset of terminal respiratory region of
150 day-old FVB control mouse lung.
A) Light microscopic image of toluidine blue stained thick section of
terminal respiratory portion of lung from FVB control mouse. Alveolar
ducts (AD) and alveolar sacs (AS) dominate the field. Small rectangle
indicates the area shown by TEM in the inset. x110.
B) Inset transmission electron micrograph illustrates pulmonary
components typically located in the small rectangular region shown in
figure 2A. A rich pulmonary capillary network separated from the air
space by the respiratory filtration barrier is the primary feature of this
region of the lung. Intravascular cells include lymphoctyes (L) and
erythrocytes (Ec) A type I alveolar cell (A2) is located in the respiratory
septum between alveoli. X2,500.
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Figure 3.

Transmission electron micrograph of 150 day-old FVB control mouse
lung. Endothelial cells (En) line the inside of the blood-air barrier. Type I
alveolar cells (A1) cover its external surface. Pulmonary alveolar
basement membrane separated these two cells types. A type II alveolar
cell (A2) is shown in the upper right corner of the micrograph. x16,000.
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Figure 4.

Transmission electron micrograph of two adjacent respiratory filtration
barriers in lung of 150 day-old FVB control mouse. Endothelial cells (En)
line the intravascular surface of the blood-air barrier, while type I alveolar
cells (A1) line the air space of the barrier. The pulmonary alveolar
basement membrane (PABM) is located between the two cell types and is
indicated by the arrowhead. X60,000.
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Figure 5.

Representative transmission electron micrographs of respiratory filtration
barriers in 60 day-old FVB, Jtmt, OVE, and OVEJtmt mice. Figures A-D
illustrate typical blood-air barriers in FVB, Jtmt, OVE, and OVEJtmt mice
at identical magnifications. Visual observation suggests that pulmonary
alveolar basement membranes (located between opposing arrowheads)
exhibit similar widths. x60,000.
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Figure 6.

Representative transmission electron micrographs of respiratory filtration
barriers in 150 day-old FVB, Jtmt, OVE, and OVEJtmt mice. Figures A-D
illustrate typical blood-air barriers in FVB, Jtmt, OVE, and OVEJtmt mice
at identical magnifications. Preliminary visual observations suggest that
pulmonary alveolar basement membranes (located between opposing
arrows are show similar thicknesses, except for the severely diabetic
(OVE) animals indicated in Figure 5C. x60,000.
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Figure 7.

Mean pulmonary alveolar basement membrane thickness in 60 day-old
mice. Non-transgenic background control mice (FVB), transgenic mice
overexpressing metallothionein in endothelial cells (Jtmt), transgenic
diabetic mice (OVE), and bi-transgenic diabetic mice overexpressing
metallothionein in endothelial cells (OVEJtmt). FVB versus OVEJtmt
show statistically significant differences. Statistically significant
difference (P <0.05).
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Figure 8.

Mean pulmonary alveolar basement membrane thickness in 150 day-old
mice. Non-transgenic background control mice (FVB), transgenic mice
overexpressing metallothionein in endothelial cells (Jtmt), transgenic
diabetic mice (OVE), and bi-transgenic diabetic mice overexpressing
metallothionein in endothelial cells (OVEJtmt). FVB versus OVE, Jtmt
versus OVEJtmt and OVE versus OVEJtmt show statistically significant
differences. Statistically significant difference (P <0.05).
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Figure 9.

Age-related mean pulmonary alveolar basement membrane thickness in
60 day-old and 150 day-old mice. Statistical significance is shown
between OVE 60 and 150 day-old mice (P = 0.01). P value is set at p <
0.05.

Table 3. Age-related mean pulmonary alveolar basement membrane thickness in
60 and 150 day-old mice.
Genotype
Age (Days) Mean width Age-related Age-related
Statistical
+S.D. in
change in
percentage Significance
nanometers
thickness
change
(P <0.05)
FVB
60
49.11 ± 5.13
FVB
150
48.71 ± 6.63 - 0.4 nm
- 0.8%
N.S.
Jtmt
60
50.01 ± 7.38
Jtmt
150
52.76 ± 4.79 + 2.75 nm
+ 5.4%
N.S.
OVE
60
49.37 ± 6.29
OVE
150
58.42 ± 6.93 + 9.09 nm
+ 18.3%
P = 0.44
OVEJtmt
60
44.97 ± 4.76
OVEJtmt
150
47.75 ± 8.01 + 2.78
+ 6.1%
N.S.
Numerical comparison of pulmonary alveolar basement membrane thickness in 60 and
150 day-old non-transgenic background control mice (FVB), transgenic mice (Jtmt),
transgenic diabetic mice (OVE), and bi-transgenic diabetic mice overexpressing
metallothionein in endothelial cells (OVEJtmt) ± S.D.
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Figure 10.

Representative light micrographs of paraffin embedded kidney cortex and
lung immunohistochemically stained for MTII.
A) Jtmt kidney. Negative control; primary antibody omitted.
B) Jtmt kidney
C) FVB lung. Negative control, primary antibody omitted.
D) FVB lung.
E) Jtmt lung. Negative control, primary antibody omitted.
F) Jtmt lung.
MT I/II staining was observed in proximal tubules of the kidney. Light
staining was observed in the alveolar-capillary network of the FVB lung
and more intense staining was observed in the Jtmt lung.
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Figure 11.

Average pulmonary MT I/II (µg/mg total tissue protein) in FVB control
(n=2), Jtmt transgenic (n=2), OVE (n=2) and OVEJtmt (n=2) transgenic
and bi-transgenic animals. In Jtmt mice, MT I/II was approximately a twofold increase over the FVB control. In the OVEJtmt MT I/II measured
approximately 0.5 fold higher than the FVB control.
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